Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/25513
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Robinson, Philip C | - |
dc.contributor.author | Liew, David F L | - |
dc.contributor.author | Liew, Jean W | - |
dc.contributor.author | Monaco, Claudia | - |
dc.contributor.author | Richards, Duncan | - |
dc.contributor.author | Shivakumar, Senthuran | - |
dc.contributor.author | Tanner, Helen L | - |
dc.contributor.author | Feldmann, Marc | - |
dc.date | 2020-12-18 | - |
dc.date.accessioned | 2020-12-15T04:27:55Z | - |
dc.date.available | 2020-12-15T04:27:55Z | - |
dc.date.issued | 2020-12-03 | - |
dc.identifier.citation | Med 2020; 1(1): 90-102 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/25513 | - |
dc.description.abstract | Coronavirus disease 2019 (COVID-19) currently has few effective treatments. Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search for treatments continue. An exaggerated inflammatory state is likely responsible for much of the morbidity and mortality in COVID-19. Elevated levels of tumor necrosis factor (TNF), a key pro-inflammatory cytokine, have been shown to be associated with increased COVID-19 mortality. In patients with rheumatoid arthritis, TNF blockade reduces not only biologically active TNF but other pro-inflammatory cytokines important in COVID-19 hyperinflammation. Observational data from patients already on anti-TNF therapy show a reduced rate of COVID-19 poor outcomes and death compared with other immune-suppressing therapies. Anti-TNF has a long history of safe use, including in special at-risk populations, and is widely available. The case to adequately assess anti-TNF as a treatment for COVID-19 is compelling. | en |
dc.language.iso | eng | |
dc.subject | SARS-CoV-2 | en |
dc.subject | coronavirus disease-2019 | en |
dc.subject | glucocorticoids | en |
dc.subject | pandemic | en |
dc.subject | tumor necrosis factor | en |
dc.subject | COVID-19 | en |
dc.title | The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Med | en |
dc.identifier.affiliation | Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA | en |
dc.identifier.affiliation | Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK | en |
dc.identifier.affiliation | Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK | en |
dc.identifier.affiliation | University of Queensland Faculty of Medicine, Herston, Queensland, Australia | en |
dc.identifier.affiliation | Department of Medicine, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia | en |
dc.identifier.affiliation | Department of Medicine, University of Melbourne, Parkville, Victoria, Australia | en |
dc.identifier.affiliation | Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK | en |
dc.identifier.doi | 10.1016/j.medj.2020.11.005 | en |
dc.type.content | Text | en |
dc.identifier.pubmedid | 33294881 | |
local.name.researcher | Liew, David F L | |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | Rheumatology | - |
crisitem.author.dept | Clinical Pharmacology and Therapeutics | - |
crisitem.author.dept | Clinical Pharmacology and Therapeutics | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.